WO2025016391 - THIAZOLE PYRAZINE COMPOUNDS AND USE THEREOF
National phase entry is expected:
Publication Number
WO/2025/016391
Publication Date
23.01.2025
International Application No.
PCT/CN2024/105861
International Filing Date
17.07.2024
Title **
[English]
THIAZOLE PYRAZINE COMPOUNDS AND USE THEREOF
[French]
COMPOSÉS DE THIAZOLE PYRAZINE ET LEUR UTILISATION
[Chinese]
噻唑并吡嗪类化合物及其应用
Applicants **
SIMCERE ZAIMING PHARMACEUTICAL CO., LTD.
Inventors
LI, Zhen
CHEN, Lei
SUN, Tianwen
ZHAO, Zihao
ZHANG, Fan
LI, Zhengtao
Priority Data
202310882781.0
18.07.2023
CN
202410628488.6
21.05.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2666 | |
| EPO | Filing, Examination, Granting | 19023 | |
| Japan | Filing, Examination, Granting | 2464 | |
| South Korea | Filing, Examination, Granting | 2835 | |
| USA | Filing, Examination, Granting | 7390 |
Total:
34,378
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Provided are thiazole pyrazine compounds represented by formulas (I), (II), (III) and (IV), or pharmaceutically acceptable salts or stereoisomers thereof, a pharmaceutical composition containing same, and a use thereof in the preparation of a drug for preventing or treating a DNA polymerase theta-mediated disease.[French]
L'invention concerne des composés de thiazole pyrazine représentés par les formules (I), (II), (III) et (IV), ou des sels ou stéréoisomères pharmaceutiquement acceptables de ceux-ci, une composition pharmaceutique les contenant, et leur utilisation dans la préparation d'un médicament pour la prévention ou le traitement d'une maladie médiée par l'ADN polymérase thêta.[Chinese]
提供了一种式(I)、(II)、(III)、(IV)所示的噻唑并吡嗪类化合物或其药学上可接受的盐或其立体异构体，含有它们的药物组合物以及其在制备预防或者治疗DNA聚合酶θ介导的疾病的药物中的应用。